The GSK (LSE: GSK) share price is a nightmare and there’s little sign of respite ... I remember the glory days when, as ...

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

Global stock markets are set for a positive weekly close following the Fed’s jumbo rate cuts. The Bank of England’s hawkish ...

The hand sanitizer spray pen market is projected to grow at a CAGR of 11% over the forecast period, reaching a market value ...

In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have increased from $2.09 to $2.38. The consensus estimate for 2025 earnings has improved from $4.33 to $7.31. Year to date, shares of ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

The user of the website is referred to as "you" and "your". By posting on our share chat boards you are agreeing to the following: If you are going to post non-English, please also post an English ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...